{
  "ticker": "TYP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960866",
  "id": "02960866",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250623",
  "time": "0933",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250623/pdf/06l02jhr7snz67.pdf",
  "summary": "- **Clinical Trial Approval**: Received ethics approval for open-label study of TRP-8803 (IV-infused psilocin) in Binge Eating Disorder (BED) patients.  \n- **Trial Details**:  \n  - 12 patients to receive two doses 14 days apart, with first dosing in Q3 CY25 and top-line results expected Q4 CY25.  \n  - BED is the most common eating disorder in the US and second in Australia, with significant unmet need.  \n- **Potential Upside**: Data may indicate TRP-8803's utility in treating BED comorbidities (depression, anxiety, PTSD).  \n- **Prior Data**: Phase 2a study with oral psilocybin (TRP-8802) showed >80% reduction in BED scores.  \n\n*No capital markets or liquidity-impacting information identified.*",
  "usage": {
    "prompt_tokens": 3101,
    "completion_tokens": 179,
    "total_tokens": 3280,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-22T23:47:39.715755"
}